Go back to the main page.
Transforming Today's Science Into Tomorrow's Cures
Samaritan's collaborative researchers have made important patented discoveries in the fields of, central nervous system diseases, such as, Alzheimer's disease; cancer; cardiovascular disease; and infectious diseases, such as, AIDS, and Hepatitis C. These discoveries have positioned us with a rich pipeline of new drugs with novel mechanisms of actions to develop.
Samaritan Pharmaceuticals, Inc. is an entrepreneurial biopharmaceutical company focused on the development and marketing of innovative therapeutics. At Samaritan Pharmaceuticals our mission has been to create life-saving drugs for people suffering from AIDS, Alzheimer’s, heart disease and cancer. View all the latest press releases and news articles focused on Samaritan Pharmaceuticals, Inc. These publications, called peer-reviewed journals, are scholarly periodicals requiring each article submitted be judged by an independent panel of experts (scientific peers) to authenticate the accuracy of the material. The number of articles printed and the variety of publications accepting the article serve to underscore the legitimacy of information. Samaritan has collaborative relationships with other pharmaceutical companies to commercialize branded approved prescription products in selected niche territories, such as, in Greece, Albania, Bosnia, Bulgaria, Croatia, Cyprus, Czech Republic, Egypt, FYROM, Hungary, Montenegro, Poland, Romania, Serbia, Slovakia, Slovania, Syria and Turkey. Before a drug can be offered to the public it must go through several phases of rigorous testing to make sure it is safe, efficient and does what it says it can do. The testing is mandated and overseen by the U.S. Food and Drug Administration (FDA) which is part of the U.S. Department of Health and Human Services. SAMARITAN PIPELINE - (MECHANISM OF ACTION VIDEOS)
Go back to the main page. Contact Samaritan Pharmaceuticals, Inc. Find what you are looking for in our website.
EXECUTIVE BIOGRAPHIES

Dr. James E.K. Hildreth, M.D.
The work of Dr. Hildreth in HIV/AIDS dates back to 1986 and focuses on blocking HIV infection by learning how HIV gets into cells. He has published more than 80 scientific articles and holds six patents. Originally from Arkansas, Dr. Hildreth holds degrees from Harvard University, Oxford University and Johns Hopkins University where he was the first African American to earn full professorship with tenure in the basic sciences.

Currently, Dr. Hildreth serves as the Director for the Center for AIDS Health Disparities Research and Professor of Medicine at Meharry Medical College in Nashville, Tennessee. Dr. Hildreth is also an Adjunct Professor of Pharmacology and Molecular Sciences, at Johns Hopkins School of Medicine, Baltimore, Maryland.

In addition, Dr. Hildreth is a past member of the National Institutes of Health/the National Institute of Allergy and Infectious Diseases (AIDS Research Review Study Section). His research has been focused on the relationship between adhesion molecules, lipid rafts, and the biology of human retroviruses (HIV).

Back to Board of Directors

Back to Science and Technology Advisory Committee

Partnering
Opportunities